TAS2R42: A Potential Drug Target and Biomarker for Taste Receptors

Target Name: TAS2R42

NCBI ID: G353164

TAS2R42

TAS2R42: A Potential Drug Target and Biomarker for Taste Receptors

Abstract:
TAS2R42, a member of the Taste Receptor Type 2 (TRT2) family, has been identified as a potential drug target and biomarker for taste disorders, neurodegenerative diseases, and psychiatric disorders. This article summarizes the current understanding of TAS2R42, its potential drug targets, and its potential as a biomarker for disease diagnosis and treatment.

Introduction:
Taste is a crucial sense that contributes to our overall quality of life. The sense of taste involves the perception and identification of chemical compounds in food, such as sweet, salty, sour, and bitter flavors. Taste is mediated by the Taste Receptors (TRs), which are G protein-coupled receptors (GPCRs) that play a central role in taste perception. TRs are divided into four subfamilies: TR1, TR2, TR3, and TR4. TR2 subfamily members, including TAS2R42, are involved in the perception of sour and bitter flavors.

Drug Targets:
TAS2R42 is a TR2 subfamily member that is expressed in the taste buds of the tongue and inner lining of the mouth. It is known to function as a negative taste sensor that binds to the TR2 receptor, which is responsible for the perception of sour and bitter flavors. The binding of TAS2R42 to the TR2 receptor can modulate the activity of TR2-containing GPCRs, leading to changes in taste perception.

TR2 receptor antagonists, such as those used to treat taste disorders likeburning mouth syndrome (BMS), have been shown to alleviate symptoms by blocking the TR2 receptor and reducing the activity of TR2-containing GPCRs. Therefore, TAS2R42 could be a potential drug target for treating taste disorders.

Biomarkers:
TAS2R42 has also been identified as a potential biomarker for several psychiatric disorders, including major depressive disorder (MDD), anxiety, and schizophrenia. The levels of TAS2R42 have been shown to be altered in individuals with MDD, anxiety, and schizophrenia, and these changes may contribute to the symptoms these disorders exhibit. Therefore, TAS2R42 could be a promising biomarker for these disorders.

Pathophysiology:
TAS2R42 is involved in the modulation of TR2 receptor function by binding to the TR2 receptor. This interaction between TAS2R42 and TR2 receptors leads to changes in TR2 receptor activity, which can ultimately modulate taste perception. TAS2R42 has been shown to interact with several other TR2 subfamily members, including TR3 and TR4, which are involved in the perception of sweet andumami flavors, respectively.

TAS2R42 signaling is also involved in the regulation of ion channels in taste taste buds, which plays a role in the perception of different taste features. The TR2 receptor is known to activate voltage-gated channels, such as the TRPV1 and TRPV2 channels, which are involved in the perception of pain and inflammation.

Conclusion:
TAS2R42 is a TR2 subfamily member that is involved in the perception of sour and bitter flavors. Its potential as a drug target for treating taste disorders and as a biomarker for psychiatric disorders makes it an attractive target for future research. Further studies are needed to fully understand the role of TAS2R42 in taste perception and its potential as a drug and biomarker.

Protein Name: Taste 2 Receptor Member 42

Functions: Receptor that may play a role in the perception of bitterness and is gustducin-linked. May play a role in sensing the chemical composition of the gastrointestinal content. The activity of this receptor may stimulate alpha gustducin, mediate PLC-beta-2 activation and lead to the gating of TRPM5 (By similarity)

The "TAS2R42 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TAS2R42 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets